Home   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  • Wnt/Stem Cell
  • Epigenetics
∨
  >  
JAK

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

JAK

Chemical Structure Cat. No. Product Name CAS No.
Ilginatinib Chemical Structure
 BCP44119 Ilginatinib 1239358-86-1
Ilginatinib is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. JAK2/Src inhibitor NS-018 competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, NS-018 inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis.
Aurora B inhibitor 1 Chemical Structure
 BCP42843 Aurora B inhibitor 1 937276-52-3
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
BD750 Chemical Structure
 BCP42671 BD750 892686-59-8
BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively.
SB1317 Chemical Structure
 BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
SHR0302 Chemical Structure
 BCP34833 SHR0302 1445987-21-2
SHR0302 is a novel potent JAK inhibitor, blocking JAK/STAT3 signaling, suppressing proliferation, migration and collagen production, and inducing the apoptosis of hepatic stellate cells.
Deuruxolitinib Chemical Structure
 BCP36774 Deuruxolitinib 1513883-39-0
AZD-4205 Chemical Structure
 BCP36112 AZD-4205 2091134-68-6
AZD4205 is a novel potent and selective janus kinase 1 (JAK1) inhibitor.
Gusacitinib hydrochloride Chemical Structure
 BCP35707 Gusacitinib hydrochloride 2228989-14-6
Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM.
TG-89 Chemical Structure
 BCP35054 TG-89 936091-56-4
TG-89 is an inhibitor of JAK2, FLT3, RET and JAK3.
Delgocitinib Chemical Structure
 BCP34832 Delgocitinib 1263774-59-9
Delgocitinib is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
123下一页末页共 82 条记录 1 / 9 页 
0086-15971444841